LongevityLow Risk

Retinalamin

Also known as: Retinal bioregulator, Khavinson retinal peptide, bovine retina peptide

Half-life:: Unknown

Administration Routes

parabulbar injectionintramuscular injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Polypeptide bioregulator from bovine retina; normalizes retinal pigment epithelial and photoreceptor cell function; reduces oxidative damage in retinal tissue

A retinal tissue bioregulator from the Khavinson series. Protects and restores retinal function; studied for age-related macular degeneration, diabetic retinopathy, and glaucoma.

Primary Research Areas

retinal cell protection
visual function restoration
macular degeneration support
anti-aging (eyes)

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian retinal peptide bioregulator (Khavinson Institute). Used in Russia for age-related retinal degeneration. Not FDA-approved. Not available in US except as research chemical.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Retinalamin

No active associated providers listed yet.